NCT06508775 is a long-term follow-up of patients previously treated with Miltenyi CAR T products. Interventions: MB-CART19.1 (anti-CD19 CAR T), MB-CART20.1 (anti-CD20 CAR T), and MB-CART2019.1 (dual CD19/CD20 CAR T). Type: autologous, genetically modified T cells (lentiviral-transduced) expressing chimeric antigen receptors. Mechanism: CARs bind CD19 and/or CD20 on B-lineage cells, triggering CAR signaling (CD3ζ plus co-stimulatory domains), T-cell activation, expansion, cytokine release, and targeted cytotoxicity, leading to depletion of malignant B cells. Targets: B-cell antigens CD19 and CD20 on ALL/NHL/CLL tumor cells (and B-cell populations), engaging T-cell effector pathways downstream of CAR/TCR signaling. The study monitors long-term safety, efficacy, CAR persistence, and late events.